Create the tools enabling discovery and better health O U R M I S S I O N 1 1. Preliminary unaudited full year results for 2023.​ 2. The Company is guiding full year 2023 GAAP gross margin percentage to be in the

Preliminary unaudited full year results for 2023. 2. The Company is guiding full year 2023 GAAP gross margin percentage to be in the high 50's, and non-GAAP gross margin percentage to be approximately 50%. GAAP gross margin does not include shipping and handling costs, which include freight and other activities costs associated with product shipments.

Non-GAAP gross margin includes these shipping and handling costs. GAAP Gross Margin2 Biomarkers Publications Revenue1 Cash burn1 : QTRX Unmatched Technology >950 Instruments installed Early penetration in multi-billion diagnostics CLIA lab running validated neuro LDTs Non-GAAP Gross Margin2 Built to lead neuro decade 2 Strong Results Operational Leverage Clear Strategy Research Power the neuro decade with unique biomarkers Diagnostics Establish and grow the AD diagnostics business Lab Services capability >0.75M tests per year (improvement of 50%) Manufacturing capacity >4M tests per year (improvement of 300%) Innovation rate >20 assays per year (development times reduced from >18 months to <6 months) Double digit top-line growth1 Non-GAAP GM2 of appr. 50% Improvement of 1200 bps Strong Balance Sheet >$300M1 in net cash Annual cash burn1 down by >3x 1.

Non-GAAP gross margin includes these shipping and handling costs.